Objectives: Liver transplantation remains the only effective long-term treatment option for patients with end-stage liver disease (ESLD). Organs available for ESLD patients are scarce and it increasingly important to utilize extended criteria donors, including livers with steatosis. Outcomes of moderately macrosteatotic allografts have acceptable outcomes in certain patients but pose a challenging clinical problem.

Methods: A total of 1114 consecutive patients undergoing liver transplant with pretransplant allograft biopsy were retrospectively reviewed. Donor and recipient characteristics, short and long-term outcomes of patients receiving allografts with mild (<30%) and moderate (>30%) macrosteatosis and patient and allograft survival were compared.

Results: 70 patients received allografts with moderate macrosteatosis. Donor and recipient characteristics were similar between both groups.

We found that patient survival and allograft survival was negatively impacted by moderate macrosteatosis on log-rank test. This effect did not remain statistically significant on the multivariate analysis, after controlling for donor age, recipient age, cold ischemia time and MELD at time of transplantation.

Conclusion: Moderately macrosteatotic liver allografts can be used safely for transplantation and have short and long-term outcomes that are comparable to mildly macrosteatotic or non-steatotic allografts after controlling for potentially confounding variables.

CITATION INFORMATION: Alvikas J., Deeb A-.P., Lemon K., Chen X., Malik S., Zeng G., Hughes C., Humar A., Tevar A. Outcomes of Moderately Macrosteatotic Liver Allografts Am J Transplant. 2017;17 (suppl 3).

« Back to 2018 American Transplant Congress